HomeBiotechnologyMicrofluidX raises £3.3M for superior remedy platform

MicrofluidX raises £3.3M for superior remedy platform

MicrofluidX (MFX), a U.K. primarily based supplier of next-generation bioreactors for cell analysis and manufacturing, has introduced £3.3 million ($4 million) of secured investments. This brings the corporate’s whole funding to this point to £7 million ($8.5 million). 

MicrofluidX’s subsequent technology platform, the Cyto Engine, addresses the necessity for an inexpensive, scalable cell tradition platform to revolutionize analysis, facilitate large-scale manufacture, and allow widespread entry to superior therapies.  

The most recent spherical of funding has been secured from Longwall Ventures, UKI2S, Perscitus, J.B. Ugland Enterprise AS, Puffin Level Ltd, and Esco LifeSciences.

“Superior remedy manufacturing is hindered by outdated, insufficient manufacturing applied sciences,” stated Antoine Espinet, CEO of MicrofluidX . 

“Our purpose to commoditize manufacturing for cell and gene therapies via automation, digitalization, and the adoption of machine studying is supported by our buyers, who admire the unimaginable affect this might have on the cell and gene remedy sector, and finally sufferers all over the world.”

MicrofluidX addressing ache factors

MicrofluidX stated it’s addressing the 2 massive ache factors confronted by the superior therapies trade, commercialization and medical translation. 

By offering a scalable bioprocessing platform with full integration of on-line course of analytical instruments and knowledge analytics powered by machine studying, the corporate hopes the Cyto Engine will scale back the fee and time of superior remedy improvement and assist convey these life-saving remedies to sufferers. 

Along with product improvement, the brand new funding can be used to arrange additional exterior trials with finish customers, together with the lately introduced pilot manufacturing feasibility line with VTT Finland and Jabil Healthcare. This follows the profitable trials automating the enlargement of T cells with the Cell and Gene Catapult, and mesenchymal stem cells with Stemmatters.

“We’re charging ahead on our mission to develop probably the most exact, scalable, automated bioprocessing platform for the cell and gene manufacturing sector. We need to convey precision biology to sufferers, and we’re grateful to our funders for serving to us to take action,” Espinet stated.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments